HK1198646A1 - 取代的咪唑並噠嗪類化合物及其用途 - Google Patents

取代的咪唑並噠嗪類化合物及其用途

Info

Publication number
HK1198646A1
HK1198646A1 HK14112109.7A HK14112109A HK1198646A1 HK 1198646 A1 HK1198646 A1 HK 1198646A1 HK 14112109 A HK14112109 A HK 14112109A HK 1198646 A1 HK1198646 A1 HK 1198646A1
Authority
HK
Hong Kong
Prior art keywords
substituted imidazopyridines
imidazopyridines
substituted
Prior art date
Application number
HK14112109.7A
Other languages
English (en)
Inventor
Markus Follmann
Johannes-Peter Stasch
Gorden Redlich
Alexander Straub
Jens Ackerstaff
Nils Griebenow
Andreas Knorr
Frank Wunder
Volkhart Min-Jian Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198646A1 publication Critical patent/HK1198646A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK14112109.7A 2011-05-06 2014-12-02 取代的咪唑並噠嗪類化合物及其用途 HK1198646A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011075398A DE102011075398A1 (de) 2011-05-06 2011-05-06 Substituierte Imidazopyridazine und ihre Verwendung
PCT/EP2012/058048 WO2012152630A1 (de) 2011-05-06 2012-05-02 Substituierte imidazopyridazine und ihre verwendung

Publications (1)

Publication Number Publication Date
HK1198646A1 true HK1198646A1 (zh) 2015-05-22

Family

ID=46197232

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112109.7A HK1198646A1 (zh) 2011-05-06 2014-12-02 取代的咪唑並噠嗪類化合物及其用途

Country Status (8)

Country Link
US (1) US9150580B2 (zh)
EP (1) EP2705038A1 (zh)
JP (1) JP6100756B2 (zh)
CN (1) CN103842363B (zh)
CA (1) CA2834903A1 (zh)
DE (1) DE102011075398A1 (zh)
HK (1) HK1198646A1 (zh)
WO (1) WO2012152630A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6056872B2 (ja) 2012-11-30 2017-01-11 アステラス製薬株式会社 イミダゾピリジン化合物
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
JP6748113B2 (ja) 2015-05-06 2020-08-26 バイエル・ファルマ・アクティエンゲゼルシャフト 全身性硬化症（ＳＳｃ）に付随する指潰瘍（ＤＵ）を治療するための単独のまたはＰＤＥ５阻害剤と組み合わせたｓＧＣ刺激剤、ｓＧＣ活性化剤の使用
SI3325013T2 (sl) 2015-07-23 2023-11-30 Bayer Pharma Aktiengesellschaft Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba
AU2016371762A1 (en) 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
JP7101688B2 (ja) 2016-10-11 2022-07-15 バイエル・ファルマ・アクティエンゲゼルシャフト ｓＧＣ刺激薬とミネラルコルチコイド受容体拮抗薬とを含む組み合わせ
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
WO2018188590A1 (en) 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
WO2019219672A1 (en) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
MA53127A (fr) 2018-07-11 2021-05-19 Cyclerion Therapeutics Inc Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
MX2007011600A (es) * 2005-03-21 2007-12-07 Lilly Co Eli Compuestos de imidazopiridazina.
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
CN101981033B (zh) * 2008-02-06 2015-02-04 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
DE102009004245A1 (de) * 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators

Also Published As

Publication number Publication date
JP6100756B2 (ja) 2017-03-22
DE102011075398A1 (de) 2012-11-08
US9150580B2 (en) 2015-10-06
WO2012152630A1 (de) 2012-11-15
US20140113900A1 (en) 2014-04-24
EP2705038A1 (de) 2014-03-12
CN103842363A (zh) 2014-06-04
CN103842363B (zh) 2017-09-26
CA2834903A1 (en) 2012-11-15
JP2014513113A (ja) 2014-05-29

Similar Documents

Publication Publication Date Title
HK1190710A1 (zh) 氟烷基取代的吡唑並吡啶及其用途
HK1198698A1 (zh) 取代的增環嘧啶及其用途
AP2014007731A0 (en) Substituted triazolopyridines and their use as TTKinhibitors
HK1198646A1 (zh) 取代的咪唑並噠嗪類化合物及其用途
GB201111705D0 (en) Compounds and their use
HK1191034A1 (zh) -羧烷基耳他汀類及其應用
IL231082A (en) Pyrimido compounds - pyridazinone and their use
GB201111630D0 (en) Novel compounds and their use
EP2697386A4 (en) DESIGN AND USE OF PEPDUCINE
GB201114448D0 (en) Compounds and their use
GB201004886D0 (en) The Hoppon
GB201115344D0 (en) The FitCase
HK1198587A1 (zh) 異噻唑並吡啶- -甲酰胺和它們作為藥物的用途
GB201009016D0 (en) The SealCase
GB201115921D0 (en) The Denness fast-loo
GB201018845D0 (en) The gauntlag
GB2497001B (en) The hand
GB201204735D0 (en) The quadtrolley
GB201104444D0 (en) Compounds and their use
GB201120676D0 (en) The degravitator
GB201112500D0 (en) The degravitator
GB201112308D0 (en) The degravitator
GB201110618D0 (en) The gilabead
GB201110314D0 (en) The lughole
GB201108973D0 (en) The fledge